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Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer Jason B. Ross 1 , Doowon Huh 1 , Lisa B. Noble 1 and Sohail F. Tavazoie 1, 2 Through in vivo selection of multiple ER-negative human breast cancer populations for enhanced tumour-forming capacity, we have derived subpopulations that generate tumours more efficiently than their parental populations at low cell numbers. Tumorigenic-enriched subpopulations exhibited increased expression of LAMA4, FOXQ1 and NAP1L3-genes that are also expressed at greater levels by independently derived metastatic subpopulations. These genes promote metastatic efficiency. FOXQ1 promotes LAMA4 expression, and LAMA4 enhances clonal expansion following substratum detachment in vitro, tumour re-initiation in multiple organs, and disseminated metastatic cell proliferation and colonization. The promotion of cancer cell proliferation and tumour re-initiation by LAMA4 requires β1-integrin. Increased LAMA4 expression marks the transition of human pre-malignant breast lesions to malignant carcinomas, and tumoral LAMA4 overexpression predicts reduced relapse-free survival in ER-negative patients. Our findings reveal common features that govern primary and metastatic tumour re-initiation and identify a key molecular determinant of these processes.
Cancer progression is characterized by the formation of tumours in primary organs and subsequent re-formation of tumours in metastatic sites [1] [2] [3] [4] . During primary tumorigenesis, malignant cancer cells invade into the surrounding stromal compartment and must survive and proliferate in the absence of their previous attachment to the basement membrane or other extracellular matrix (ECM) proteins 5 . These early steps of malignant tumour formation can be experimentally modelled by primary xenograft 'tumour re-initiation' assays, which assess the capacity of human cancer cells implanted into a primary organ site to re-initiate tumours in a secondary host 6 . Although comparison of cancer cells with differing tumorigenic capacities has led to the discovery of many important biological mediators of tumour-forming potential [7] [8] [9] , the relationship of highly tumorigenic cells to metastatic disease has not been systematically explored 10, 11 , and whether the primary tumour-forming potential of cancer cells is sufficient to also enable the propagation of tumours at distant sites during metastatic progression is a question of considerable interest 10 .
To investigate the biological features and molecular determinants governing primary and metastatic tumour re-initiation, we developed an unbiased approach to select for cells with enhanced tumourforming capacity. Analogous to the previous use of in vivo selection to select for and study highly metastatic subpopulations 4, [12] [13] [14] [15] [16] [17] , we sought to select subpopulations of cancer cells that phenotypically demonstrate enhanced tumour-forming capacity. We focused on oestrogen receptor-negative (ER-negative) breast cancer, an aggressive subset of breast cancer in need of targeted therapies 18 . We subjected multiple ER-negative human breast cancer cell populations to in vivo selection for enhanced tumour re-initiation capacity in a xenograft model. This strategy yielded tumorigenic-enriched (TE) populations that demonstrated enhanced tumour re-initiation capacity in multiple organ microenvironments. Transcriptomic profiling of TE subpopulations revealed a set of genes-LAMA4, FOXQ1 and NAP1L3-to be expressed at greater levels in these cells relative to their parental populations. These genes were also expressed at greater levels by highly metastatic cells independently derived from the same parental populations, and each of these genes promoted metastatic efficiency in vivo. Further characterization of LAMA4 revealed it to enhance proliferation during substratum-detachment in vitro, tumour re-initiation in multiple microenvironments, the proliferation of disseminated metastatic cells, and the formation of micro-metastatic colonies in vivo. The ability of LAMA4 to drive cancer cell proliferation and tumour re-initiation requires β1-integrin. In early breast cancer lesions, malignant breast cancer cells express higher levels of LAMA4 relative to pre-malignant cells, and LAMA4 expression in established tumours stratifies ER-negative breast cancer patients into those with worse relapse-free survival (LAMA4 high) and those with improved relapse-free survival (LAMA4 low). Collectively, our selection for subpopulations of cells with enhanced tumour-forming potential establishes a robust model to interrogate the molecular basis of tumour re-initiation across multiple organ sites. These findings have uncovered a key molecular determinant of these processes in breast cancer, and validate this unbiased approach for discovery of genes and phenotypes that govern re-initiation by malignant cells.
RESULTS
In vivo selection for tumour re-initiation enriches for populations with enhanced tumour-forming capacity To study the biology that governs breast cancer tumour re-initiation, we used in vivo selection to select for subpopulations of human 3 MDA-parental or MDA-TE3 cells were injected directly into the lung parenchyma to assess ectopic tumour re-initiation capacity. Lung bioluminescence was measured on day 53 and normalized to post-injection signal at day 0 (a). n = 7 independent mice. On day 53 lungs were sectioned, vimentin stained, and the number of macroscopic nodules per lung was counted (b). n = 3 lungs from 3 independent mice. Scale bars, 1 mm. Insets are magnified ×5. (c,d) 1 × 10 5 CN34-parental or CN34-TE2 cells were injected directly into the lung parenchyma to assess ectopic tumour re-initiation capacity. Lung bioluminescence was measured on day 56 and normalized to postinjection signal at day 0 (c). n = 8 (CN34-parental), n = 9 (CN34-TE2) independent mice. On day 56 lungs were sectioned, vimentin stained, and the number of macroscopic nodules per lung was counted (d). n = 8 (CN34-parental), n = 9 (CN34-TE2) lungs from independent mice. Scale bars, 1 mm. Insets are magnified ×5. (e,f) 1 × 10 5 MDA-parental or MDA-TE3 cells were injected into the portal circulation through splenic injection to assess metastasis to the liver. Liver colonization was measured by bioluminescence imaging at day 35 normalized to post-injection signal at day 0 (e). n = 5 independent mice. On day 35 livers were sectioned, vimentin stained, and the number of macroscopic nodules was counted (f). n = 5 livers from 5 independent mice. Scale bars, 1 mm. Insets are magnified ×5. (g,h) 2 × 10 5 CN34-parental or CN34-TE2 cells were injected into the portal circulation through splenic injection to assess metastasis to the liver. Liver colonization was measured by bioluminescence imaging on day 56 and normalized to post-injection signal at day 0 (g). n = 4 independent mice. On day 56 livers were sectioned, vimentin stained, and the number of macroscopic nodules was counted (h). n = 4 livers from 4 independent mice. Scale bars, 1 mm. Insets are magnified ×5. * P < 0.05, * * P < 0.01, * * * P < 0.001 were obtained using a one-sided Mann-Whitney test (a,c,e,g) or a one- and NAP1L3 led to a significant reduction in metastasis based on bioluminescence imaging over 56 days normalized to day 0 post-injection signal (e). n = 8 (control shRNA), n = 8 (LAMA4 shRNA1), n = 7 (NAP1L3 shRNA1), n = 7 (FOXQ1 shRNA1) independent mice. Representative vimentin-stained lungs and quantification of macroscopic lung nodules on day 56 (f). n = 4 (control shRNA), n = 5 (LAMA4 shRNA1), n = 4 (NAP1L3 shRNA1), n = 5 (FOXQ1 shRNA1) lungs from independent mice. Scale bars, 1 mm. Insets are magnified ×5. (g,h) 5 × 10 4 CN34-LM1a cells transduced with control shRNA, or shRNAs targeting LAMA4, FOXQ1 or NAP1L3 were injected intravenously into immunodeficient mice. shRNA depletion of LAMA4, FOXQ1 and NAP1L3 led to a significant reduction in metastasis based on bioluminescence over 84 days normalized to day 0 post-injection signal (g). n = 26 (control shRNA), n = 6 (LAMA4 shRNA1), n = 5 (NAP1L3 shRNA1), n = 5 (FOXQ1 shRNA1) independent mice. Representative vimentin-stained lungs and quantification of macroscopic lung nodules on day 84 (h). n = 5 (control shRNA), n = 3 (LAMA4 shRNA1), n = 3 (NAP1L3 shRNA1), n = 3 (FOXQ1 shRNA1) lungs from independent mice. Scale bars, 1 mm. Insets are magnified ×5. * P < 0.05, * * P < 0.01, * * * P < 0.001 obtained using one-sided Student's t-test (c,d,f,h), or one-sided Mann-Whitney test (e,g). All data are represented as mean + or ± s.e.m.
breast cancer cells with enhanced tumour-forming capacity. We applied selective pressure for tumour re-initiation at low cell numbers by injecting increasingly limiting numbers of breast cancer cells orthotopically into the mammary fat pads of immunodeficient mice to generate xenograft tumours over successive rounds of serial dilution ( Fig. 1a ). Independent tumorigenic human breast cancer cell lines, the MDA-MB-231 (MDA-231) line 14, 19 and the minimally passaged CN34 line 16 , were subjected to in vivo selection. These cell lines were selected on the basis of their ER-negative status 20 . Following injection into the mammary fat pads of immunodeficient mice, both cell lines gave rise to tumours at non-saturating (less than 100%) frequencies at the initial cell doses used (10,000 or 20,000 cells, for the MDA-231 or CN34 cell lines, respectively) during the first round of in vivo selection ( Fig. 1b ). Multiple additional rounds of in vivo selection yielded TE derivatives MDA-TE3 and CN34-TE2 ( Fig. 1b ), which were propagated and expanded in vitro. TE derivatives gave rise to xenograft tumours at significantly greater frequencies when injected into the mammary fat pads of immunodeficient mice at low cell numbers (100 or 2,000 cells, for the MDA-231 or CN34 cell lines, respectively) relative to their respective parental populations, demonstrating their enhanced orthotopic tumour reinitiation capacity ( Fig. 1c,d ). Subsequent in vitro experiments revealed that the TE derivatives surprisingly proliferated and formed colonies to a lesser extent than their parental populations in standard adherent cell culture conditions ( Supplementary Fig. 1a-d ), did not demonstrate significant differences in their capacity to attach to tissue-culture plates ( Supplementary Fig. 1e ,f), and did not recruit a greater number of endothelial cells relative to their parental populations ( Supplementary Fig. 1g ,h). These findings suggested that the enhanced in vivo tumour-forming capacity demonstrated by TE derivatives was independent of multiple in vitro phenotypes typically considered to confer a pro-tumorigenic advantage. In addition, immunophenotypic characterization of the MDA-TE3 or CN34-TE2 derivatives did not reveal enrichment of CD44 + /CD24 − marker profiles relative to their respective parental populations ( Supplementary Fig. 1i ,j). Collectively, these results demonstrate that subpopulations of cells with significantly enhanced tumour re-initiation capacity can be derived from human breast cancer populations through in vivo selection.
TE populations exhibit enhanced colonization of multiple ectopic organs relative to their parental populations
The relationship between primary tumour-forming potential and metastatic activity is a fundamental question of great interest in cancer biology 10, 21, 22 . Although highly tumorigenic cells have been posited to be more able to metastasize 23 , some studies have suggested these processes to be independent 8, 24 . As a first step to address this issue, we examined whether TE derivatives were more effective at re-initiating tumours in a metastatic organ relative to their parental populations. When injected directly into the lung parenchyma, TE derivatives gave rise to a greater number of macroscopic colonies in the lungs relative to their respective parental populations ( Fig. 2a-d ), demonstrating that they were enriched in ectopic tumour re-initiation capacity in addition to orthotopic tumour re-initiation capacity. This finding prompted us to consider whether the enhanced tumour-forming potential of TE cells was sufficient to enhance their colonization of organs during metastasis. As organ-specific features such as the endothelial tight junctions of the lungs represent significant barriers to cell extravasation 25, 26 , we reasoned that the TE derivatives might demonstrate an increased capacity to metastasize to an organ with less stringent requirements for trans-endothelial migration, whereby colonization is primarily driven by tumour-forming capacity. When we assessed the capacity of TE cells to metastasize to the liver, an organ whose fenestrated sinusoidal capillaries more readily permit cell seeding 27 , they gave rise to a significantly greater number of macroscopic colonies in the liver relative to their respective parental populations ( Fig. 2e-h ). Taken together, these findings indicate that in vivo selection for orthotopic tumour re-initiation is sufficient to coselect for enhanced colonization of multiple organs.
LAMA4, FOXQ1 and NAP1L3 exhibit increased expression levels in TE and highly metastatic cells and promote metastatic efficiency
Having selected for TE derivatives with enhanced tumour re-initiation capacity, we next used a systematic approach to identify genes that might govern this process. We first focused on genes whose expression was greater in TE cells relative to their parental populations. Wholegenome transcriptomic profiling of TE derivatives from the MDA-231 and CN34 cell lines revealed a large set of genes (169, Supplementary Table 1 ) that exhibited at least 1.5-fold greater expression in these cells relative to their respective parental populations ( Fig. 3b ). Interestingly, this list contained several genes that were expressed at greater levels in highly lung-metastatic (LM) cells (derived through in vivo selection of the MDA-231 and CN34 cell lines) 14 , relative to the same parental populations, an overlap that was highly statistically significant (P = 2.91 × 10 −6 ). We posited that the set of genes expressed at greater levels in both TE and highly metastatic derivatives might represent general regulators of tumour re-initiation whose function was not restricted to the organ of selection or features specific only to primary tumour formation or metastasis ( Fig. 3a) . Comparison of the set of genes that exhibited greater expression in the TE derivatives (Supplementary Table 1 ) and in LM sub-lines (Supplementary Table 2 ) that were previously derived from the MDA-231 (ref. 14) and CN34 (ref. 16 ) cell lines revealed 8 candidate genes that exhibited a greater than 1.5fold increased expression in all in vivo-selected derivatives relative to their respective parental populations ( Fig. 3b and Supplementary  Table 3 ). Quantitative real-time PCR validation of this set yielded three genes-LAMA4, FOXQ1 and NAP1L3-that exhibited significantly greater levels of expression in TE and LM derivatives from both cell lines relative to their respective parental populations ( Fig. 3c,d) .
LAMA4 encodes the secreted alpha chain isoform protein laminin-α4, an ECM component mainly present in basement membranes 28 .
FOXQ1 is a member of the FOX family of transcription factors with roles in development 29 and cancer progression 30 . NAP1L3 encodes a poorly characterized member of the nucleosome assembly protein (NAP) family 31 .
The increased expression of LAMA4, FOXQ1 and NAP1L3 in TE and highly metastatic derivatives relative to their parental populations led us to speculate that these genes might regulate tumour reinitiation. As a first step to assess the function of these genes, we investigated whether they regulated the formation of macroscopic nodules by highly metastatic cells. Knockdown of LAMA4, FOXQ1 or (f) 5 × 10 5 MDA-TE3 cells transduced with either control shRNA or two independent shRNAs targeting LAMA4 were injected into the mammary fat pads of immunodeficient mice. There were no significant differences in the size of the tumours formed on day 39. n = 8 independent mammary fat pad injections (pooled from 2 mice with 4 injections each per condition). (g,h) 1 × 10 2 MDA-TE3 cells transduced with either control shRNA or an shRNA targeting LAMA4 were injected directly into the lung parenchyma to assess ectopic tumour re-initiation capacity. Lung bioluminescence was measured on day 63 and normalized to day 0 postinjection signal (g). n = 5 independent mice. On day 63 lungs were sectioned, vimentin stained, and the number of macroscopic nodules per lung was counted (h). n = 5 lungs from 5 independent mice. NAP1L3 in highly metastatic MDA-LM2 and CN34-LM1a derivatives significantly decreased lung metastatic colonization as quantified by bioluminescence imaging (Fig. 3e ,g and Supplementary Fig. 2a -c), and histological analysis of lungs from these mice revealed fewer macro-metastases formed following knockdown of each of these genes ( Fig. 3f ,h). Collectively, these findings reveal a set of genes (LAMA4, FOXQ1 and NAP1L3) whose expression is increased in subpopulations independently selected for enhanced tumorigenic and metastatic activity, and whose individual expression promotes metastatic efficiency in vivo.
LAMA4 promotes tumour re-initiation in multiple organ microenvironments
Having identified a set of genes (LAMA4, FOXQ1 and NAP1L3) expressed at greater levels in cells with enhanced tumorigenic and metastatic potential and that individually enhanced metastatic efficiency, we focused on one of these genes, LAMA4, for further study. Our focus on LAMA4 was based on its greater fold expression increase in in vivo-selected derivatives relative to FOXQ1 and NAP1L3, and its encoding of a secreted ECM protein that could potentially be therapeutically targeted. Consistent with its extracellular role, we detected greater levels of LAMA4 protein, laminin-α4, in conditioned media obtained from TE cells relative to their parental populations ( Supplementary Fig. 3a -c). We also observed that laminin-α4 was distributed throughout xenograft tumours, with greater levels in tumours derived from TE cells relative to tumours derived from parental cells ( Supplementary Fig. 3d ,e). LAMA4 depletion in a third independent ER-negative breast cancer cell line also led to a significant reduction in macroscopic lung colonization ( Supplementary Fig. 4a,b ), further supporting the potential importance of this gene in ER-negative breast cancer. We next investigated whether LAMA4 was sufficient to enhance the tumour re-initiation capacity of parental breast cancer populations. Overexpression of LAMA4 in parental populations significantly increased (fourfold) the number of tumours formed after injection of low numbers of cells (10 cells per injection) into the mammary fat pads of immunodeficient mice (Fig. 4a ). In the context of injecting a high number of cells (5 × 10 5 cells per injection), overexpression or depletion of LAMA4 did not significantly alter tumour growth, as there were no significant differences in tumour size (Fig. 4b,f ), and LAMA4 depletion had no effect on the frequency of tumours formed ( Supplementary Fig. 4f ). Overexpression of LAMA4 in both the MDA-231 and CN34 parental populations also led to a significant increase in metastatic colonization of the lungs following tail-vein injection of cancer cells ( Fig. 4c and Supplementary Fig. 4c ), resulting in a significant increase in the number of macroscopic colonies formed ( Fig. 4d and Supplementary Fig. 4d ). Taken together, these results demonstrate that overexpression of LAMA4 in parental populations is sufficient to enhance both their tumorigenic and metastatic potential at limiting cell numbers.
We next assessed the role of endogenous LAMA4 in TE derivatives and found that LAMA4 depletion in TE3 cells significantly decreased the numbers of tumours formed following orthotopic injection of limiting numbers of cells (10 cells per injection) into the mammary fat pads of immunodeficient mice ( Fig. 4e and Supplementary  Fig. 4e ). LAMA4 depletion in TE3 cells also significantly decreased the numbers of macroscopic colonies formed following ectopic injection into the lungs (Fig. 4g,h and Supplementary Fig. 4g ,h). Collectively, these findings reveal that LAMA4 is sufficient to enhance the tumour-forming and metastatic potential of parental populations, that endogenous expression of LAMA4 promotes tumour re-initiation in multiple organ microenvironments, and that the impact of LAMA4 on tumour re-initiation emerges in the physiological context of limiting cell numbers.
LAMA4 promotes cancer cell proliferation in the absence of substratum attachment in vitro in a β1-integrin-dependent manner An important feature of malignant cells is their capacity to proliferate and survive in the absence of attachment to an underlying matrix during multiple stages of cancer progression 5,32,33 -conditions that can lead to protracted cell-cycle arrest or programmed cell death 34 . We reasoned that the cell-autonomous expression of LAMA4 by cancer cells might enable them to proliferate irrespective of attachment to an underlying substratum. When TE3 cells were seeded at clonal density (one cell per well) into low-attachment plates that prevent substratum attachment ( Supplementary Fig. 5a ), LAMA4-depleted cells proliferated at a reduced level relative to cells transduced with a control hairpin ( Fig. 5a ). We next investigated whether TE and highly metastatic derivatives, which physiologically express elevated levels of LAMA4 relative to their parental populations, might demonstrate an enhanced ability to proliferate in the absence of substratum attachment. TE3 or LM2 cells seeded at clonal density into low-attachment plates proliferated more extensively than their parental population ( Fig. 5b ). In addition, after several days, a greater fraction of wells seeded with TE3 and LM2 cells contained multiple cells relative to wells seeded with the parental population, which had a greater fraction of wells that still contained only one cell ( Supplementary Fig. 5b ). This effect was LAMA4-dependent, as a smaller fraction of wells containing LAMA4-knockdown cells contained multiple cells relative to wells containing control cells ( Supplementary Fig. 5c ). These observations suggested that LAMA4 might regulate cell-cycle dynamics during conditions when cells are detached from substratum. Modification of this assay to enable quantitative cell-cycle analysis ( Supplementary Fig. 5d ) revealed that LAMA4 depletion in the absence of substratum attachment increased the fraction of cells in G0/G1 ( Fig. 5c and Supplementary Fig. 5e ). TE3 and LM2 populations cultured under the same conditions contained a smaller fraction of cells in G0/G1 relative to their parental populations ( Fig. 5d ). Taken together, these findings demonstrate that in the absence of substratum attachment in vitro, LAMA4 represses the fraction of cells in G0/G1 and promotes the proliferation of these breast cancer cells.
We next performed more detailed studies to understand how LAMA4 impacts cell proliferation. The accumulation of cells in G0/G1 in the absence of substratum attachment in vitro suggested that cellcycle inhibitory proteins, such as p21 or p27, might be impacted [35] [36] [37] . We found that LAMA4 depletion led to increased levels of p27 in the absence of substratum attachment in vitro ( Fig. 5e and Supplementary  Fig. 5l ). LAMA4 depletion also decreased the fraction of Ki-67-positive TE3 cells in the absence of substratum attachment in vitro ( Fig. 5f and Supplementary Fig. 5f ), consistent with these findings. We next investigated whether LAMA4 acts through integrins, which are known to be receptors for laminins [38] [39] [40] [41] and have well-described roles in cell proliferation 42, 43 . Inhibition of β1-integrin using a blocking antibody decreased the proliferation of TE cells in the absence of substratum either control shRNA or two independent shRNAs targeting LAMA4 were injected intravenously into immunodeficient mice and lung bioluminescence was measured over time (e). n = 6 (control shRNA), n = 4 (LAMA4 shRNA1), n = 4 (LAMA4 shRNA2) independent mice. On day 28 lungs were collected, sectioned, and stained with vimentin and Ki-67. Through fluorescence image acquisition using confocal microscopy and software analysis, the average size of metastatic colonies was quantified (f; representative backgroundsubtracted vimentin-stained images, right; scale bars, 100 µm), the number of solitary single cells relative to multicellular colonies (micro-metastases) was quantified (g; see f for representative images; red closed arrows, micrometastases; brown open arrows, solitary cells), and the percentage of solitary single cells that stained positively for Ki-67 was quantified (h; vimentin staining in green; Ki-67 staining in red; arrows depict solitary cells; scale bars, 25 µm). n = 4 lungs from 4 independent mice. Micro-mets, micrometastases. * P < 0.05, * * P < 0.01, * * * P < 0.001 were obtained using a onesided Student's t-test (a-h). All data are represented as mean + or ± s.e.m. attachment in vitro ( Fig. 5i and Supplementary Fig. 5g ,k). Inhibition of an independent integrin, αVβ3-integrin, did not have a significant effect ( Fig. 5i ). Similar results were found in MDA-parental cells that overexpressed LAMA4 ( Fig. 5g and Supplementary Fig. 5i ). Inhibition of β1-integrin also prevented the ability of recombinant LAMA4containing protein (laminin-411) to promote the proliferation of TE3 LAMA4-knockdown cells ( Fig. 5h and Supplementary Fig. 5h,j) . Finally, extension of these findings in vivo revealed that inhibition of β1-integrin also prevented the increase in ectopic tumour reinitiation by LAMA4-overexpressing cells (Fig. 5j,k) . These results demonstrate that the promotion of cancer cell proliferation and tumour re-initiation by LAMA4 requires β1-integrin.
LAMA4 promotes metastatic proliferation and incipient micro-metastasis formation in vivo During metastasis, cancer cells detach from the primary tumour and subsequently enter a foreign microenvironment with a distinct ECM composition acutely devoid of proliferative and survival cues that permit the effective formation of colonies 4, 44 . In addition, studies have shown that introduction of cancer cells into the intravenous circulation leads to the pulmonary seeding of mainly solitary cells that initially lack contact with each other 45 . These features represent barriers that can prevent the ability of cancer cells to regain proliferative potential and to re-initiate metastatic colonies, and they share several similarities with the seeding of single cells in non-attachment conditions in vitro. On the basis of our findings that LAMA4 promotes the proliferation of cancer cells under such in vitro conditions, we reasoned that LAMA4 may also regulate the initial proliferation of disseminated cancer cells and their subsequent formation of multicellular colonies in vivo. To address this, we seeded highly metastatic LM1a cells with or without LAMA4-knockdown into the lungs of mice through intravenous injection. After a latency period of several days, lung-bioluminescence signal from mice injected with LM1a-control cells began to increase, in contrast to signal from mice injected with LM1a-LAMA4-knockdown cells, which showed persistently reduced signal ( Fig. 6a ). Measurement of cancer cellderived caspase-3/7 activity through an in vivo reporter during this same period revealed no significant differences between animals injected with control cells relative to those injected with LAMA4knockdown cells, demonstrating that the differences we observed in early metastatic outgrowth were unlikely to be secondary to apoptosis ( Supplementary Fig. 6a ). Rather, these observations were consistent with LAMA4 promoting the proliferation and expansion of incipient cells that had extravasated into the lungs. Subsequent analysis revealed that LAMA4 depletion resulted in a significant decrease in the fraction of multicellular colonies relative to single cells present in the lungs of mice several days after tail-vein injection (Fig. 6c ), demonstrating that LAMA4 promotes the formation of micro-metastases in vivo. LAMA4 depletion also reduced the percentage of solitary cells that stained positively for the proliferative marker Ki-67 ( Fig. 6d ), demonstrating that a greater fraction of solitary LAMA4-knockdown cells were not actively proliferating. Furthermore, knockdown of LAMA4 also decreased the average size of metastatic colonies formed ( Fig. 6b and Supplementary Fig. 6b ), consistent with the continued proliferation of control cells giving rise to larger colonies relative to knockdown cells. An independent experiment employing the highly metastatic LM2 cell line confirmed these observations (Fig. 6e-h and Supplementary Fig. 6c ). Collectively, these findings demonstrate that LAMA4 promotes the active proliferation of disseminated solitary cells and the formation and expansion of incipient multicellular micro-metastases in vivo.
FOXQ1 promotes the expression of LAMA4
Having demonstrated a functional role for LAMA4 in promoting primary and metastatic tumour re-initiation, we next examined whether its expression level is influenced by either FOXQ1 or NAP1L3, two other genes expressed at greater levels in TE and highly metastatic derivatives that also promote metastatic efficiency. Depletion of FOXQ1 in multiple cell lines decreased LAMA4 levels (Fig. 7a,b) , and depletion of LAMA4 in multiple cell lines decreased FOXQ1 levels (Fig. 7c,d) , revealing a positive reciprocal relationship between these genes. This relationship was further supported through interrogation of a large set of primary breast tumour samples (n = 988; see Methods), which revealed that LAMA4 expression positively correlates with FOXQ1 expression (Fig. 7e ). NAP1L3 knockdown in multiple cell lines did not reduce LAMA4 expression ( Supplementary Fig. 7a,b) and LAMA4 knockdown did not reduce NAP1L3 expression ( Fig. 7c,d) .
These results demonstrate that LAMA4 expression co-varies with FOXQ1 in primary human tumours and reveal a positive reciprocal relationship between FOXQ1 and LAMA4 expression.
Increased expression of LAMA4 marks early breast cancer progression and is correlated with clinical relapse
Given the increased expression of LAMA4 by TE derivatives and its sufficiency in promoting tumour re-initiation in vivo, we next investigated the role of LAMA4 in human clinical samples. As breast cancers transition from the pre-malignant stage (ductal carcinoma in situ) to the malignant stage (frank carcinoma), cancer cells acquire the ability to proliferate and survive in the absence of proper engagement to the ECM as they pass through the basement membrane and enter the surrounding stromal microenvironment 46 . Having demonstrated a role for LAMA4 in driving the expansion of breast cancer cells in the settings of non-attachment in vitro and multiple microenvironments in vivo, we examined whether LAMA4 expression was increased during the transition from premalignancy to malignancy. Examination of multiple transcriptomic data sets [47] [48] [49] [50] of laser-capture micro-dissected breast cancer tissues from pre-malignant or malignant areas of disease from within the same patients (Fig. 8a , see Methods) revealed that LAMA4 expression was significantly increased in malignant breast cancer cells relative to nearby pre-malignant cancer cells ( Fig. 8b-e ; P < 0.0001 combined). These findings are consistent with the increased expression of LAMA4 in populations of cells enriched for tumour-forming potential and support our functional studies demonstrating a role for LAMA4 in promoting breast cancer tumour re-initiation.
We next investigated whether LAMA4 expression in established tumours correlates with relapse of human breast cancer. Analysis of multiple independent data sets [51] [52] [53] [54] revealed that when patients with ER-negative breast cancer were stratified into those whose tumours expressed high or low levels of LAMA4, patients whose tumours expressed high levels of LAMA4 had significantly reduced relapsefree survival relative to patients whose tumours expressed low levels of LAMA4 ( Fig. 8f -i, P < 0.0005 combined). Tumours from patients that relapsed also expressed higher levels of LAMA4 ( Fig. 8k ) and increased expression of LAMA4 was associated with shorter overall survival in an independent cohort of ER-negative patients (Fig. 8j ). Collectively, our selection and characterization of cancer cell populations with enhanced tumorigenic capacity establishes a model to study molecular and cellular determinants of tumour-forming potential, and has led to the identification of LAMA4 as a key promoter of tumour reinitiation in the primary and metastatic microenvironments, whose expression correlates with human breast tumorigenesis and clinical outcome (Fig. 8l ).
DISCUSSION
A molecular and cellular understanding of the features that govern tumour-forming potential is of great interest to the scientific and biomedical communities 6 . We herein describe a strategy to elucidate genes and cellular features that govern tumour re-initiation in ERnegative breast cancer using an unbiased approach to enrich for populations of cells with enhanced tumorigenic capacity (Fig. 1) . TE populations derived through in vivo selection demonstrated enhanced tumour re-initiation in multiple microenvironments (Figs 1 and 2 ) and expressed a set of genes (LAMA4, FOXQ1 and NAP1L3) at greater levels relative to their parental populations (Fig. 3) . These genes were also expressed at greater levels by highly metastatic cells and each of these genes promoted metastatic efficiency in vivo (Fig. 3 ). Further characterization of LAMA4 revealed it to promote tumour reinitiation in the primary and metastatic microenvironment ( Fig. 4) and to enhance the proliferation and multicellular expansion of cancer cells in the absence of substratum attachment in vitro ( Fig. 5 ) and during colonization in vivo ( Fig. 6) . Mechanistically, the promotion of cancer cell proliferation and tumour re-initiation by LAMA4 requires β1-integrin (Fig. 5 ). In patient samples, LAMA4 expression is increased in malignant cancer cells relative to adjacent pre-malignant cancer cells ( Fig. 8 ) and increased LAMA4 expression is correlated with reduced relapse-free survival (Fig. 8 ). Our unbiased application of in vivo selection to derive subpopulations of cells with enhanced tumorigenic capacity has enabled the identification of cellular and molecular determinants of tumour re-initiation in breast cancer and revealed LAMA4 as a gene that promotes tumour re-initiation in multiple microenvironments and whose increased expression is associated with human breast cancer initiation and progression ( Fig. 8) .
It is thought that cancer cell interactions with the microenvironment during multiple stages of cancer progression can enable cells to resume cell-cycle progression and expand into colonies when they lack important extracellular cues 34, 44, 55, 56 that can result in proliferative suppression 57 or cellular quiescence 34 . Our findings that the cell-autonomous expression of LAMA4 promotes the proliferation of cancer cells in the absence of substratum attachment in vitro and during incipient metastatic outgrowth in vivo suggest that LAMA4 antagonizes the suppressive effects these contexts can have on proliferative potential. The promotion of tumour re-initiation by LAMA4 in orthotopic and ectopic settings is also consistent with this gene governing a general feature of tumour re-initiation that is independent of a particular microenvironment.
LAMA4 is a member of a family of laminin genes encoding proteins normally present in the ECM (ref. 58) . The roles of various laminins is thought to be restricted to their deposition into the basement membrane and ECM, which is thought to enable cancer progression in part by allowing cancer cells to anchor to these surfaces to survive and proliferate [59] [60] [61] . LAMA4 is distinct from most laminin alpha-chains in that it lacks an amino-terminal 'head' region that is thought to allow laminins to polymerize de novo 62 . Studies have revealed that LAMA4 requires enzymatic crosslinking to be incorporated into ECM generated in vitro 63 and have proposed a de-adhesive role for LAMA4 in the progression of other solid cancers 64 . The cell-autonomous expression by cancer cells of this specific laminin gene lacking an anchoring head region provides a potential mechanism for cells to decouple proliferative capacity from the physiologically constrained requirement of attachment to an immobile ECM, allowing them to in effect 'carry' their own ECM. Future studies could determine the potential contributions of other laminin family members that cooperate with LAMA4 in mediating its effects.
In women, breast cancer leads all other cancers in the numbers of annual diagnoses and deaths incurred globally 65 . Although aggressive cancers can lead to rapid death, metastatic relapse can occur even after the surgical resection of the primary tumour and without any previous radiographic evidence of metastases 44 . Such relapse is thought to be caused by a small number of disseminated cells that have re-activated proliferative potential in an inhospitable microenvironment 11, 34, 57 . Our identification of LAMA4 as a gene expressed by ER-negative breast cancer cells that promotes tumour re-initiation in the metastatic microenvironment reveals a candidate target for therapeutic intervention. Functional blocking of LAMA4 protein could potentially prevent the re-activation and subsequent outgrowth of disseminated metastatic cells. Our identification of this gene as a potential therapeutic target in ER-negative breast cancer has important implications for patients diagnosed with ER-negative subtypes, given that they are not candidates for treatment with antioestrogen therapies 66 .
METHODS

Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper METHODS Animal studies. All mouse experiments were conducted in accordance with a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at The Rockefeller University. Six-to twelve-week-old age-matched female NOD scid or NOD scid gamma mice obtained from Jackson Labs were used for orthotopic mammary fat pad, experimental lung metastasis, ectopic direct-lung, and experimental liver metastasis assays. For bioluminescence tracking of cells in vivo, cells were labelled with a triple-fusion reporter protein construct 67 through retroviral transduction followed by FACS to isolate GFP-positive transduced cells 48-72 h later. Non-invasive bioluminescence imaging was performed by anaesthetizing mice with isoflurane (Butler Schein), retro-orbital injection of D-luciferin luciferase (PerkinElmer) and exposing mice in an IVIS Lumina II (Caliper Life Science). Quantification of signal was performed with Living Image (PerkinElmer) software. In vivo caspase activity was measured by retro-orbital injections of VivoGlo Caspase 3/7 Substrate (Z-DEVD-aminoluciferin sodium salt; Promega) and bioluminescence signal was normalized to cancer cell luciferase signal 68 . Tumour volume was determined by measuring the small (s) and large (l) diameter of tumours using an Electronic Digital Caliper (Fisher Scientific) and quantifying volume using the formula πs 2 l/6.
In vivo selection.
To generate tumorigenic-enriched (TE) derivatives from the MDA-MB-231 and CN34 human breast cancer cell lines, moderate numbers of parental populations (1 × 10 4 MDA-231-parental or 2 × 10 4 CN34-parental cells) were mixed in a 1:1 ratio of PBS and growth-factor-reduced Matrigel (356231, BD Biosciences) and injected orthotopically and bilaterally into the second and fourth mammary glands of NOD scid mice. Tumours that were generated were dissociated into single cells (see below) and propagated in vitro to yield first-generation TE (TE1) derivatives. TE1 cells were then subjected to another round of in vivo selection by injecting tenfold less (1 × 10 3 MDA-TE1 or 2 × 10 3 CN34-TE1) cells into the mammary fat pads of NOD scid mice, giving rise to a second round of tumours that were dissociated into single cells and propagated in vitro to yield second-generation TE (TE2) derivatives. For the MDA-231 cell line, a third round of in vivo selection was performed by injecting MDA-TE2 cells at a dose tenfold less (1 × 10 2 cells) into the mammary fat pads of NOD scid mice to give rise to a third round of tumours that were then dissociated into single cells and propagated in vitro to yield third-generation TE3 derivatives. CN34-TE2 cells did not undergo a third round of in vivo selection.
Tumour dissociation. For tumour dissociation, tumours were excised, placed in a 6 cm tissue-culture dish and minced into fine pieces using a scalpel. Cells were collected in a 50 ml conical tube by washing with PBS using a 25 ml pipette and spun down. The pellet was resuspended in 5 ml of ACK buffer (Cambrex) and incubated at room temperature for 10 min for lysis of red blood cells. The mixture was washed with PBS, spun down, and resuspended in 10 ml of dissociation media comprised of a 1:1 mixture of DMEM/F12 supplemented with penicillin, streptomycin, Fungizone 1.25 mg ml −1 , collagenase type I (Worthington Biochemical) and 1 mg ml −1 hyaluronidase (Worthington Biochemical). The mixture was placed in a shaking incubator at 37 • C. Every 30 min, the mixture was removed and pipetted up and down with a 25 ml pipette for a maximum of 2 h until the mixture had little or no large pieces remaining. After dissociation, PBS was added to the mixture and it was spun down for 10 min. The pellet was resuspended in 7 ml of 0.25% trypsin-EDTA (Invitrogen) and placed in a shaking incubator at 37 • C. After 10 min, 30 ml of 10% FBS-containing DMEM was added to neutralize trypsin and the solution was spun down at 3,000 r.p.m. (1,952g ) for 10 min. The pellet, now mainly a fine suspension, was resuspended in 10 ml of a 1:1 mixture of DMEM/F12 supplemented with penicillin, streptomycin, Fungizone 1 mg ml −1 , BSA, 25 mM HEPES, and 20,000 units l −1 DNase I (Worthington Biochemical) and placed in a shaking incubator at 37 • C. After 10 min, the pellet was resuspended in 10 ml of PBS and spun down. The final suspension was filtered through a 70 µm and then 40 µm filter to enrich for a single-cell suspension of cells. The resulting cells were plated onto adherent tissueculture plates and grown in appropriate media.
Orthotopic and ectopic tumour re-initiation assays. For orthotopic tumour re-initiation assays, cancer cells were mixed in a 1:1 ratio of PBS and growthfactor-reduced Matrigel (356231, BD Biosciences) and injected bilaterally into the second and fourth mammary glands of age-matched NOD scid or NOD scid gamma mice. After 10 weeks, mice were euthanized and necropsy was performed. Absence of tumour re-initiation was concluded if there was no evidence of tumour growth through visual inspection and palpation on detailed necropsy. Any visual or palpable evidence of tumour growth was considered a re-initiating event and counted as positive tumour formation. For quantification, n was the number of independent mammary fat pad injections sites (4 per mouse). For ectopic tumour re-initiation assays, cancer cells were mixed in a 1:1 ratio of PBS and growth-factorreduced Matrigel (356231, BD Biosciences) and injected into the third intercostal space, 3 mm deep, directly into the lung parenchyma of age-matched NOD scid or NOD scid gamma mice. For the ectopic tumour re-initiation blocking antibody experiment, mouse IgG1 isotype control antibody (clone 107.3, BD Pharmingen) or mouse anti-human β1-integrin blocking antibody (clone 6S6, Millipore) was added to the cell/PBS/Matrigel mixture at a concentration of 20 µg ml −1 before injection. For ectopic tumour re-initiation assays, n was the number of independent mice that were injected or the number of independent lungs that were collected and subjected to histological analysis.
Metastasis assays. For lung metastasis assays, triple-reporter labelled cells were resuspended in 0.1 ml PBS and injected using a 27G1/2 needle (BD) into the lateral tail vein of age-matched NOD scid mice. For liver metastasis assays, triplereporter labelled cells were resuspended in PBS and injected using a 27G1/2 needle (BD) into the portal circulation of NOD scid gamma mice through splenic injection. For both lung and liver metastasis assays, non-invasive bioluminescence imaging was performed immediately after cell inoculations using an IVIS Lumina II (Caliper Life Science) to assess a baseline level of injected cells on day 0. For all metastasis assays, n was the number of independent mice that were injected or the number of independent lung/livers that were collected and subjected to histological analysis.
Cell culture. MDA-MB-231 (MDA-231) and CN34 breast cancer cell lines were propagated in vitro on standard tissue-culture-treated plates. MDA-MB-231 cells and their derivatives were maintained in DMEM supplemented with 10% FBS, glutamine, pyruvate, penicillin, streptomycin and Fungizone. CN34 cells and their derivatives were maintained in M199 supplemented with 2.5% FBS, 10 µg ml −1 insulin, 0.5 µg ml −1 hydrocortisone, 20 ng ml −1 EGF, 100 ng ml −1 cholera toxin, glutamine, pyruvate, penicillin, streptomycin and Fungizone. The MDA-MB-231 and CN34 parental populations and their lung-metastatic (LM) derivatives MDA-LM2 and CN34-LM1a have been described in previous publications 14, 16 . The MDA-MB-231 cell line (ATCC) was derived from the pleural effusion of a patient suffering from metastatic breast cancer 19 and the derivation of the MDA-LM2 subpopulation through in vivo selection has been described previously 14 . The CN34parental population was formerly isolated from the pleural effusion of a patient with metastatic breast cancer treated at MSKCC on IRB consent as described previously 20 and the CN34-LM1a derivative was formerly generated through inoculation of NOD scid mice with CN34-parental populations and dissociating metastatic nodules that had formed in the lungs as described previously 16 . Both cell lines are oestrogen receptor-negative 20 (ER-negative). The independent ERnegative HCC1806 cell line 69 was cultured in RPMI-based media supplemented with 10% FBS, glutamine, pyruvate, penicillin, streptomycin and Fungizone. Cells in culture were routinely tested for mycoplasma contamination. For proliferation assays in the absence of substratum attachment, cells were sorted using a FACSAria II (Becton Dickinson) at a clonal density of one cell per well into Ultra-Low Attachment Surface 96-well plates (Corning) containing EGM-2 media (Lonza). The presence of single cells was confirmed after sorting using bright-field microscopy and the number of cells contained in each well was counted on subsequent days. For quantification of cell proliferation, n was the number of individual wells seeded with single cancer cells. For the in vitro blocking antibody experiments, cells were pre-incubated with mouse IgG1 isotype control antibody (clone 107.3, BD Pharmingen), mouse anti-human αVβ3-integrin blocking antibody (clone LM609, Millipore), or mouse anti-human β1-integrin blocking antibody (clone 6S6, Millipore) at 20 µg ml −1 in HBSS for 20 min on ice before cell seeding. For the recombinant laminin-411 rescue experiments, cells were resuspended in HBSS or pre-incubated with mIgG or anti-β1-integrin antibodies at 20 µg ml −1 in HBSS for 20 min on ice, and then an equal volume of solution containing 160 nM bovine serum albumin (BSA) or 160 nM laminin-411 (BioLamina) was added to the cells and they were incubated for 30 min at 37 • C before cell seeding. For cell-cycle and Ki-67 analysis in the absence of substratum attachment, to enable quantitative analysis, a greater number of cells were seeded at a low density of 5,000 cells per well into Ultra-Low Attachment Surface 6-well plates (Corning) in media containing a 1:1 mixture of DMEM supplemented with 10% FBS, glutamine, pyruvate, penicillin, streptomycin, Fungizone, and ×2 DMEM mixed 1:1 with 3% methylcellulose stock solution (HSC001, R&D). Cells were collected on day 3 and analysed using an LSR II (Becton Dickinson). Cellcycle analysis was based on DAPI staining. For Ki-67 analysis, cells were fixed and permeabilized with BD Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences) as per the manufacturer's instructions and incubated with mouse antihuman Ki-67 antibody (Alexa Fluor 700-conjugated clone B56: BD Pharmingen) for 20 min on ice. Cell-cycle phase and Ki-67-positive fractions were determined using FlowJo (TreeStar) software. For flow cytometry immunophenotypic marker analysis, cells were incubated in PBS containing mouse anti-human CD44 antibody (APCconjugated clone G44-2: BD Pharmingen) and mouse anti-human CD24 antibody (PE-conjugated clone ML5: BD Pharmingen) for 30 min on ice. Cells were washed, DOI: 10.1038/ncb3148 stained with propidium iodide for live-dead exclusion and analysed using an LSR II (Becton Dickinson) and FlowJo (TreeStar) software.
Cell proliferation and colony formation assay. For cell proliferation assays, 2.5 × 10 4 cells were seeded into tissue-culture-treated adherent 6-well plates (Falcon). Cells were collected through trypsin digestion and counted on days 1 and 5. Cell counts were normalized to day 1. For colony formation assays, 1 × 10 2 cells were seeded in triplicate into tissue-culture-treated adherent 10 cm plates (Falcon). On day 14, plates were washed with PBS, fixed in 6% glutaraldehyde (Sigma-Aldrich), stained with 0.5% crystal violet (Sigma-Aldrich), and washed with H 2 O to better enable the visualization of colonies.
Endothelial recruitment assay. For endothelial recruitment assays, 5 × 10 4 cancer cells were seeded overnight onto tissue-culture-treated adherent 24-well plates (Falcon) and human umbilical vein endothelial cells (HUVECs; Lonza) at 70-80% confluence were serum-starved overnight. The next day, HUVECs were labelled with CellTracker Red CMTPX (Molecular Probes) according to the manufacturer's protocol and 5 × 10 4 HUVECs were seeded onto the top layer of 3 µm HTS Fluroblok Transwell inserts (BD Falcon) fitted to the top of each well of a 24-well plate. Half a millilitre of 0.2% FBS EGM-2 (Lonza) was added to the top and bottom of each well. Plates were incubated at 37 • C for 16 h. On incubation, the Transwell inserts were removed, washed twice with PBS and fixed with 4% paraformaldehyde. The inserts were then cut out using a scalpel and mounted onto microscopy slides using VECTASHIELD Mounting Media with DAPI (Vector Laboratories). For imaging and quantification, the basal side of each insert was imaged by means of fluorescence using an inverted microscope (Zeiss Axiovert 40 CFL) at ×5 and 6-9 images per field per insert were collected. Quantification of migrated HUVECs was performed using ImageJ (NIH) software http://imagej.nih.gov/ij Cell attachment assay. The cell attachment assay was performed by labelling cancer cells with CellTracker Red CMTPX (Molecular Probes) according to the manufacturer's protocol and seeding 1 × 10 5 cells per well of a standard tissue-culture six-well plate. After 18 h, each well was carefully washed with PBS and the numbers of cells that had attached cells to the tissue-culture plates was quantified. Quantification was performed by obtaining fluorescent images from nine random fields per well, subtracting background signal, and measuring the Area Fraction (the fractional area of fluorescence signal that covered each field) using ImageJ (NIH) software.
Generation of lentivirus-mediated knockdown cells. For generation of
knockdown cell lines, virus was generated using 293T cells that had been grown to 70-80% confluence. Cells were transfected with Lipofectamine 2000 in antibioticfree media and 6 µg vector A, 12 µg vector K and 12 µg of pLKO (with blasticidin or puromycin selection marker) shRNA vector. Virus was collected after 48-72 h, spun down at 2,000 r.p.m. (863g ), and filtered using 0.45 µm nylon mesh. For cell transduction, virus was added to cancer cells along with Polybrene (Millipore) and cells were incubated for 5-6 h. After at least 48 h, cells underwent antibiotic selection using either 2 µg ml −1 puromycin or 1 µg ml −1 blasticidin. Cells were removed from antibiotic selection once there were no viable cells remaining on a plate that was mock transduced. shRNA sequences are listed in Supplementary Table 4 .
Generation of retrovirus-mediated overexpressing cells. For generation of
overexpression cell lines, virus was generated using 293T cells that had been grown to 70-80% confluence. Cells were transfected with Lipofectamine 2000 in antibioticfree media and 12 µg vector gag/pol, 6 µg vector VSVG, and 12 µg of pBABE-puro empty vector or vector containing cloned full-length LAMA4. Virus was collected after 48-72 h, spun down at 2,000 r.p.m. (863g ), and filtered using 0.45 µm nylon mesh. For cell transduction, virus was added to cancer cells along with Polybrene (Millipore) for 24 h. After at least 48 h, cells underwent antibiotic selection using 2 µg ml −1 puromycin. Cells were removed from antibiotic selection once there were no viable cells left on a kill plate that was mock transduced. Primer sequences used to clone full-length LAMA4 are listed in Supplementary Table 4 .
RNA extraction and quantification of mRNA expression. Total RNA from cells was extracted and purified using the MiRvana (Applied Biosystems) or Total RNA Purification Kit (Norgen Biotek) according to the manufacturer's protocol. For mRNA quantification, 0.2-2 µg of total RNA was subject to reverse transcription using the cDNA First-Strand Synthesis Kit (Invitrogen). The resulting cDNA was diluted 1:2 or 1:5 and mixed with SYBR green PCR Master Mix (Applied Biosystems) with primers specific to each gene. Each independent reaction was split into quadruplicate wells of a 384-well plate and loaded onto an ABI Prism 7900HT Real-Time PCR System (Applied Biosystems) to conduct quantitative real-time PCR (qRT-PCR). Normalization for relative expression of target genes was performed using HPRT, GAPDH or SMAD4 as endogenous controls. Primer sequences are listed in Supplementary Table 4 .
siRNA knockdown experiments. For siRNA knockdown experiments, cells
were seeded into tissue-culture plates overnight. The following day, cells were washed with PBS, and incubated in Opti-MEM (Invitrogen) reduced-serum media. Lipofectamine 2000 (1:40, Invitrogen) and 50 nM of each specific siRNA were premixed and incubated for 20 min before being added to the cells. After addition of the Lipofectamine/siRNA mixture, the cells were incubated for 5 h, washed with PBS, and normal cell culture medium was added. For mRNA analysis, cells were collected and RNA was collected 24-30 h post-transfection. For the HCC1806 in vivo metastasis experiment, cells were injected 48 h post-transfection. Control and target gene siRNAs were obtained from Integrated DNA Technologies (IDT) or Dharmacon (Thermo Fisher Scientific). siRNA sequences are listed in Supplementary Table 4 .
Immunohistochemistry and histology. Mammary tumours, whole lungs or livers were excised and fixed through immersion in 4% paraformaldehyde overnight, and subsequently washed with PBS, 50% ethanol, 70% ethanol before being embedded in paraffin. Paraffin blocks were cut into 5-µm-thick sections. For macroscopic tumour quantification, paraffin sections were stained with mouse primary antibodies against human vimentin (1:100, clone V9, Vector Laboratories) and visualized with Vectastain ABC kit (PK-6012, Vector Laboratories) and DAB chromogen (SK-4105, Vector Laboratories); macroscopic nodules were counted on the basis of staining for vimentin. For immunofluorescence, paraffin sections underwent antigen retrieval and were stained with primary antibodies against human vimentin (1:100, Vector Laboratories) and Ki-67 (1:200, ab15580, Abcam), or for detection of endogenous laminin-α4, the mouse anti-human laminin-α4 antibody (1:50, clone 839084, R&D) was used and the isotype-matched mouse IgG1 antibody (1:50, clone 11711, R&D) was used as a control at an equivalent concentration. For detection of collagen-IV, the rabbit anti-human collagen-IV antibody (1:50, ab21295, Abcam) was used. Primary antibodies were detected using Alexa Flour dye-conjugated secondary antibodies (1:200, Invitrogen). Fluorescence was obtained using a Leica laser scanning confocal microscope (TCS SP5). Mouse on Mouse (M.O.M.) Blocking Reagent (Vector Laboratories) was used with all mouse antibodies. For solitary cell/micro-met comparisons, unprocessed images were inspected with ImageJ (NIH) software, and solitary cancer cells and multicellular micro-metastatic colonies were randomly counted in 10 fields per section or whole sections on the basis of positive staining for vimentin. Counts were quantified as the percentage of the total number of metastatic events (solitary cells + micro-metastatic colonies) to normalize for any differences in the initial seeding of metastatic cells. To compare colony size, the average colony size was quantified using ImageJ (NIH) software. To assess the proliferation of solitary cancer cells, the fraction of solitary cancer cells that stained positively for Ki-67 was quantified. This was achieved by merging unprocessed green (vimentin) and red (Ki-67) channels using ImageJ (NIH) software; the fraction of vimentin-positive solitary cancer cells that were Ki-67positive was quantified. n was the number of independent lungs that were extracted from mice.
Western blotting. For detection of laminin-α4, conditioned medium was prepared by concentrating serum-free supernatant obtained from cultured cancer cells incubated for 24 h using 100k cutoff Amicon Ultra (Millipore) centrifuge tubes. For detection of p27, p21 and β-tubulin, cell lysates were collected from cells that had been cultured overnight in Ultra-Low Attachment Surface 6-well plates (Corning). Proteins from conditioned media or cell lysates were separated using SDSpolyacrylamide gel electrophoresis, transferred to Immobilon-P Transfer Membrane (Millipore), and probed with antibodies against human laminin-α4 (1:200; clone 6C3, sc-130541, Santa Cruz Biotechnology) or p27 (1:1,000; clone D69C12, Cell Signaling Technology), p21 (1:1,000; clone 12D1, Cell Signaling Technology), or β-tubulin (1:5,000; clone 9F3, Cell Signaling Technology). Primary antibody was chemiluminescently detected using horseradish peroxidase-conjugated secondary antibody (1:10,000), ECL 2 Western Blotting Substrate (Pierce) and the SRX-101A (Konica Minolta) developer. Quantification of western blots was performed using ImageJ (NIH) software. p27 signal intensity was normalized to β-tubulin signal intensity.
Microarray hybridization and transcriptomic analysis of in vivo-selected derivatives.
To identify mRNAs whose levels were increased across TE and LM in vivo-selected derivatives as compared with their parental populations, total RNA derived from MDA-MB-231 (parental, TE3 LM2) and CN34 (parental, TE2, LM1a) populations was extracted, labelled and hybridized onto Illumina HT-12 v3 Expression BeadChip arrays by The Rockefeller University Genomics Resource Center. The raw signal intensities for each probe were median-normalized and replicates were averaged. Candidate promoters of tumour re-initiation were identified by overlapping the set of genes whose expression was at least ×1.5fold increased in the following conditions: MDA-TE3 versus MDA-parental; MDA-LM2 versus MDA-parental; CN34-TE2 versus CN34-parental; CN34-LM1a versus DOI: 10.1038/ncb3148 M E T H O D S CN34-parental. Eight candidate genes passed these criteria, and three of these genes demonstrated statistically significant differences on independent validation using quantitative real-time PCR (qRT-PCR).
Correlation coefficient analysis. Ranked expression values for LAMA4 and
FOXQ1 in primary breast tumours from 988 patients from The Cancer Genome Atlas (TCGA) Breast Cancer project provisional data set were downloaded from http://www.cBioPortal.org and subjected to a linear regression analysis. P values were based on Spearman's coefficient test. Supplementary  Table 4 ; ref. 48 and GSE14548; ref. 49) . Each data set included patient-matched laser-capture micro-dissected epithelial cancer tissue (to restrict the analysis only to cancer cells) from regions of pre-malignant (ductal carcinoma in situ) or malignant (invasive ductal carcinoma) disease. Probe intensity values for LAMA4 were used to quantify mRNA expression levels (multiple probe values were averaged) in each data set, intra-sample normalized, and subject to a paired t-test to determine statistical significance and the average fold change across individual or combined data sets. To generate Kaplan-Meier curves, for each data set patients were stratified according to those patients whose expression of LAMA4 was higher (LAMA4 High) or lower (LAMA4 Low) than the median value for all ER-negative tumour samples within that data set. ER-negativity was assessed from the clinical annotations provided with each data set. Relapse-free or overall survival outcome was censored at 5 years, plotted and subjected to a one-tailed Mantel-Cox test. For Affymetrix chips with multiple probes, only the JetSet 70 probe (202202_s_at) was used. For comparison of LAMA4 expression in tumours derived from patients that did, or did not relapse in the combined Wang/Hatzis/Desmedt/NKI data set, LAMA4 expression values were converted into z-scores within each data set before being separated into Relapse or Relapse-Free groups and the data were uncensored.
Statistical analysis. Throughout all figures: centre values represent mean, error bars
represent + or ± s.e.m.; * P < 0.05, * * P < 0.01 and * * * P < 0.001 unless otherwise noted. Statistical significance was concluded at P < 0.05. For animal studies, the investigator was not blinded during group allocation during the experiment or when assessing outcome, no statistical method was used to predetermine sample size, and the experiments were not randomized. The statistical tests used to determine P values are listed in each figure legend. Samples whose values were greater than two standard deviations from the mean were considered outliers and excluded from the analysis. Data analysed using an unpaired Student's t-test were under the assumption of normality and equal variance unless otherwise specified. For non-normal data, analysis was performed using a Mann-Whitney test; normality was assessed using a Shapiro-Wilk test. If there was a significant difference in variance, a Mann-Whitney test or Welch's correction was applied; variance was determined using an F-test. Supplementary Figure 4 LAMA4 is sufficient to promote metastatic colonization and promotes tumor re-initiation from low cell numbers (a-b) 2x10 5 HCC1806 cells transfected with either a control siRNA or two independent siRNAs targeting LAMA4 were inoculated intravenously into immunodeficient mice. siRNA depletion of LAMA4 led to a significant reduction in metastasis as measured by bioluminescence imaging on day 42 normalized to post-injection signal on day 0 (a). n = 6 independent mice. Lungs were harvested on day 42, H&E-stained, and the number of macroscopic nodules per lung section was counted. Representative lungs on day 42 (b). n = 6 (siControl), n = 5 (siLAMA4_5), n = 6 (siLAMA4_6) lungs from independent mice. Scale bars: 1mm. Insets are magnified 5x.
(c-d) 5x10 5 CN34-parental cells transduced with either an empty vector control or LAMA4 over-expression vector were inoculated intravenously into immunodeficient mice. Lung bioluminescence was measured on day 133 and normalized to post-injection signal at day 0 (c). n = 7 independent mice. Lungs were harvested on day 133, vimentin-stained, and the number of macroscopic nodules per lung section was counted. Representative vimentinstained lungs on day 133 (d). n = 7 lungs from 7 independent mice. . 4f ). Tumors were formed in all cases. n = 8 independent mammary fat pad injections (pooled from 2 mice with 4 injections each per condition). (g-h) 1x10 2 MDA-TE3 cells transduced with either a control shRNA or an independent shRNA targeting LAMA4 were injected directly into the lung parenchyma to assess ectopic tumor reinitiation capacity. Lung bioluminescence was measured on day 63 (g). n = 5 independent mice. On day 63 lungs were sectioned, vimentin stained, and the number of macroscopic nodules per lung was counted (h). n = 5 lungs from 5 independent mice. 
CN34-LM1a MDA-LM2
Supplementary Figure 6 LAMA4 does not significantly regulate apoptosis at early time points during metastatic colonization (a) 3x10 5 CN34-LM1a cells transduced with either control shRNA or an shRNA targeting LAMA4 were injected intravenously into immunodeficient mice (see Fig. 6a-b) . In vivo quantification of apoptotic cells was monitored by measurement of a luciferase-based caspase-3/7 reporter normalized to cancer cell luciferase signal over several days (left). Representative luciferase-based caspase-3/7 (non-normalized) bioluminescence signal (right). n = 5 independent mice. NS is not significant based on a two-sided Student's t-test. (b) Cumulative fraction plot depicting the distribution of metastatic foci size in the lungs of animals injected with CN34-LM1a cells that were transduced with either a control shRNA hairpin or an shRNA hairpin targeting LAMA4 (see Fig. 6a-b) . n = 5 lungs from 5 independent mice. (c) Cumulative fraction plot depicting the distribution of metastatic foci size in the lungs of animals injected with CN34-LM1a cells that were transduced with either a control shRNA hairpin or two independent shRNA hairpins targeting LAMA4 (see Fig. 6e -f). n = 4 lungs from 4 independent mice. P values were obtained using a Kolmogorov-Smirnov test. All data are represented as mean ± S.E.M. Supplementary Fig. 3 (a-c) and Supplementary Fig. 5 (l) . *Fold-change (FC) reflective the expression of (tumorigenic-enriched derivatives)/(parental populations).
Supplementary Table 1 Genes with increased expression in tumorigenic-enriched (TE) derivatives relative to parental populations Transcriptomic analysis of tumorigenic-enriched (TE) derivatives from the MDA-231 (MDA-TE3) and CN34 (CN34-TE2) cell lines were compared relative to their parental populations and genes were selected on the basis of passing a relative 1.5-fold increase cut-off criteria.
Genes with 1.5x higher expression in lung-metastatic (LM) derivatives relative to parental populations. *Fold-change (FC) reflective the expression of (lung-metastatic derivatives)/(parental populations).
Supplementary Table 2 Genes with increased expression in lung-metastatic (LM) derivatives relative to parental populations Transcriptomic analysis of lung-metastatic (LM) derivatives from the MDA-231 (MDA-LM2) and CN34 (CN34-LM1a) cell lines were compared relative to their parental populations and genes were selected on the basis of passing a relative 1.5-fold increase cut-off criteria. *Fold-change (FC) reflective the expression of (in vivo selected derivatives)/(parental populations).
MDA-LM2 FC* Gene ID
MDA-TE3 FC* CN34-TE2 FC* CN34-LM1a FC* # Supplementary Table 3 Genes with increased expression in tumorigenic-enriched (TE) and lung-metastatic (LM) cells relative to parental populations Transcriptomic analysis of TE and LM derivatives from the MDA-231 (MDA-TE3, MDA-LM2) and CN34 (CN34-TE2, CN34-LM1a) cell lines were compared relative to their parental populations and genes were selected on the basis of passing a relative 1.5-fold increase cut-off criteria in all conditions. Eight candidate promoter genes were identified.
